EDITORIAL

Why Methylene Blue Is the Only Option for Blocking the cGMP/NO Pathway in The Treatment of Vasoplegic Shock? “Reasons That Reason Itself Does Not Know…”

Paulo Roberto B. Evora¹, MD, PhD; Walter J Gomes², MD, PhD

There is no reminiscence of the word shock being used in its modern-day form before 1743. However, there is evidence that Hippocrates used the word exemia to define a state of being “drained of blood.” Shock or “choc” was first described in a trauma victim in the English translation of Henri-François LeDran’s 1740 text, Traté ou Reflexions Tirees de la Pratique sur les Playes d’armes à feu (A treatise, or reflections, drawn from practice on gun-shot wounds.) In this text, he describes “choc” as a reaction to the sudden impact. However, the first English writer to use the word shock in its contemporary meaning was James Latta in 1795¹⁰. George W. Crile, in 1899 suggested in his monograph, “An Experimental Research into Surgical Shock” that shock was a state of circulatory collapse due to excessive nervous stimulation. Other competing theories around the turn of the century included one penned by Malcolm in 1905, with the assertion that prolonged vasoconstriction led to the pathophysiological signs and symptoms observed in shock. In the following World War I, research about shock resulted in experiments by Walter B. Cannon of Harvard and William M. Bayliss of London in 1919 showing that an increase in permeability of the capillaries in response to trauma or toxins was responsible for many clinical manifestations of shock. In 1972 Hinshaw and Cox suggested a shock classification system, which is still in use today¹¹. Perhaps the best approach to defining the state of shock is that of Robert Hardaway, who begins his discussion by stating, “What shock is not.” This approach is interesting because demonstrates the entire development of circulatory shock as the pathophysiological concepts have changed. Thus, the shock is no longer: 1) Low blood pressure - due to the hypothalamus-pituitary-adrenal axis (release of catecholamines and cortisol) sustaining normal and even supranormal blood pressure; 2) a low pH does not necessarily accompany it - can be normal or even alkalotic depending on the endogenous production of bicarbonate and the compensatory hyperventilation to metabolic acidosis; 3) It is not always accompanied by low cardiac output - hyperdynamic states are associated, for example, with sepsis; 4) It is not due to the exhaustion of the adrenal gland - in pre-death, plasma levels of catecholamines are elevated; 5) Arteriolar vasodilatation does not necessarily coexist - the rule is that vasoconstriction occurs and; 6) There is not necessarily hypovolemia - an example is a cardiogenic shock resulting from acute myocardial infarction. After these considerations, it would remain to define “what shock is,” and, in search of a universal definition, it was concluded that the best definition of the shock state would be: “Inadequate capillary perfusion” or, simply, “Bad tissue perfusion.” These concepts stemming from the 1970s are linked to the Vietnam War.

¹Department of Surgery and Anatomy Ribeirão Preto School of Medicine. Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (FMRPUSP), Ribeirão Preto, SP, Brazil.
²Cardiovascular Surgery Discipline and São Paulo Hospital. Escola Paulista de Medicina. Federal University of São Paulo, São Paulo, Brazil.

DOI: 10.21470/1678-9741-2021-0957

Correspondence Address:
Paulo Roberto B. Evora
https://orcid.org/0000-0001-9631-946X
E-mail: prbevora@gmail.com
The discovery and the massive nitric oxide (NO) scientific investment annulled paradigms, starting a new era of knowledge. Vasoplegia associated with systemic inflammatory reaction was lifted to the condition of “enemy to be overcome.” The concepts emerging from the observations acquired during the first 15 years of using methylene blue (MB) for treatment of vasoplectic syndrome (VS) during cardiac surgery have established some critical topics. But, we still feel that the cyclic guanosine monophosphate (cGMP) importance is underestimated in the medical literature.

In 2009, we published a personal statement centered on MB as a treatment of VS in cardiac surgery, including fifteen years of questions, answers, doubts, and certainties\(^1\). Some repetitive observations can be applied to VS: (1) MB is safe at the recommended doses (the lethal dose is 40 mg.Kg\(^{-1}\)); (2) the use of MB does not cause endothelial dysfunction; (3) the MB effect is manifested in cases of positive NO regulation; (4) MB itself is not a vasoconstrictor, because by blocking the cGMP pathway, it releases the adenosine 3’S’ – cyclic monophosphate (cAMP) pathway, facilitating the vasoconstrictor effect of epinephrine; (5) the MB may act through this mechanism of “crosstalk,” and its use as a medication of the first choice may not be correct; (6) the most used dosage is 2 mg.Kg\(^{-1}\) in IV bolus, followed by the same continuous doses infusion because the plasma concentrations markedly decrease in the first 40 minutes. Although there are no definitive randomized controlled trials, the MB used in the treatment of VS following cardiac surgery is currently the best, safest, and cheapest option; (8) however, a possible ‘window of opportunity for the effectiveness of MB has not yet been clearly established for humans.

This editorial report has the primary purpose of performing a simple exercise of logic. It is well established\(^{3,4}\): 1. The inflammatory reaction is present in all types of circulatory shock. 2. As the vasoplegia extent goes on, a “vasoplectic endothelial dysfunction” with catecholamine-resistant arterial hypotension leads irreversibly to death. 3. This dysfunction is mediated by the cGMP / NO system and is blocked by MB. 4. Currently, the blockade of soluble guanylate cyclase (sGC) by MB, despite the most diverse criticisms, is still a matter of controversy, although this drug was first used in humans over 100 years ago.

What is the basis for the proposed logic exercise?

The NO pathway blocking is already part of the vasoplegia therapeutic arsenal. However, assuming that the MB is at least controversial, why the search for an alternative drug fall short of investment?

Following the original report in 1994, the VS was afterward met with skepticism and even denial\(^5\). However, the VS has steadily been recognized as a common complication in cardiac surgery, occurring in 20% to 27% of patients, and associated with significant morbidity and mortality. Cost analysis showed that in the United States the vasoplegia imposed an increase in ICU length of stay of 166,000 days, coming to at least $1.4 billion in cost annually. Therefore, if prevented, could potentially save in healthcare spending\(^6\).

Restrictions on MB can be disguised as a mandatory objective. From the physiological point of view, a bias toward the blockage of the cGMP/ NO pathway concealed its fundamental importance. In other words, the resistance to MB use can blunt this importance.

Quoting Blaise Pascoa’s should be “Reasons That Reason Itself does not know ...?” But the science and pharmaceutical industry are in debt.

REFERENCES

1. Saha BK, Burns SL. The story of nitric oxide, sepsis and methylene blue: a comprehensive pathophysiology review. Am J Med Sci. 2020;360(4):329-37. doi:10.1016/j.amjms.2020.06.007.
2. Evora PR, Ribeiro PJ, Vicente WV, Reis CL, Rodrigues AJ, Menardi AC, et al. Methylene blue for vasoplectic syndrome treatment in heart surgery: fifteen years of questions, answers, doubts and certainties. Rev Bras Cir Cardiovasc. 2009;24(3):279-88. doi:10.1590/s0102-76382009000400005.
3. Evora PR. An open discussion about endothelial dysfunction: is it timely to propose a classification? Int J Cardiol. 2000;73(3):289-92. doi:10.1016/s0167-5273(00)00223-0.
4. Evora PR, Alves Junior L, Ferreira CA, Menardi AC, Bassetto S, Rodrigues AJ, et al. Twenty years of vasoplectic syndrome treatment in heart surgery. Methylene blue revised. Rev Bras Cir Cardiovasc. 2015;30(1):84-92. doi:10.5935/1678-9741.20140115.
5. Gomes WJ, Carvalho AC, Palma JH, Gonçalves I Jr, Buffolo E. Vasoplectic syndrome: a new dilemma. J Thorac Cardiovasc Surg. 1994 Mar;107(3):942-3.
6. Tsouiris A, Wilson L, Haddadin AS, Yun JJ, Mangi AA. Risk assessment and outcomes of vasoplectic after cardiac surgery. Gen Thorac Cardiovasc Surg. 2017 Oct;65(10):557-565. doi:10.1007/s11748-017-0789-6.